Abstracts tagged "Abatacept"

Abstract Number: 512 • 2014 ACR/ARHP Annual Meeting
Effect and Safety of Concomitant Methotrexate and Tacrolimus on Clinical Response of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Biological Dmards
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT) is a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to…
Abstract Number: 2468 • 2014 ACR/ARHP Annual Meeting
Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis
Gerd Burmester¹, Daniel E. Furst², B G Combe³, T W J Huizinga⁴, Vivian P. Bykerk⁵, D Wong⁶, C S Karyekar⁶ and P Emery⁷, ¹Charité – University Medicine Berlin, Berlin, Germany, ²University of California at Los Angeles, Los Angeles, CA, ³Montpellier University Hospital, Montpellier, France, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Clinical remission is associated with better long-term outcomes1,2 and should be the goal of therapy in RA. In the Assessing Very Early Rheumatoid arthritis…
Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
Abstract Number: 2151 • 2014 ACR/ARHP Annual Meeting
Abatacept Related Infections: No Association with Gammaglobulin Reduction
Valquiria Dinis¹, Vilma S. T. Viana¹, Elaine P. Leon¹, Clovis A Silva², Carla G.S. Saad³, Julio C. B. Moraes³, Eloisa Bonfá³ and Ana C.M. Ribeiro⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose A recent study reported that abatacept (ABA) reduces rheumatoid arthritis (RA) related autoantibodies and gammaglobulins levels. However, the possible association of these findings with…
Abstract Number: 472 • 2014 ACR/ARHP Annual Meeting
Abatacept Can be Used Safely for RA Patients with Interstitial Lung Disease
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake³ and Katsutoshi Ando⁴, ¹[email protected], Kameda Medical Center, Kamogawa City, Japan, ²[email protected], Kameda Medical Center, Kamogawa-city, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ⁴Depertment of Respiratoly Medicine, Juntendo university, tokyo, Japan
Background/Purpose : Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of…
Abstract Number: 1966 • 2014 ACR/ARHP Annual Meeting
CTLA4-Ig (abatacept) Modulate in Vitro the ICAM1 and VEGFR-2 Expression in Human Endothelial Cells
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano², Paola Contini³, Barbara Villaggio⁴, Alberto Sulli¹, Sabrina Paolino¹, Carmen Pizzorni¹, Bruno Seriolo¹, Giuseppe Zampogna², Marco A. Cimmino¹ and Renata Brizzolara², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ³Division of Clinical Immunology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁴Research Laboratory of Nephrology, Department of Internal Medicine, University of Genova, Genova, Italy
Background/Purpose CTLA4-Ig (abatacept) is employed as biological agent in rheumatoid arthtritis (RA) treatment and interacts with the costimulatory molecule CD86 expressed by different cells involved…
Abstract Number: 328 • 2014 ACR/ARHP Annual Meeting
Etanercept, Abatacept and Anakinra Treatment Ameliorates Inflammation and Pain in a Novel Mono-Arthritic Multi-Flare Model of Streptococcal Cell Wall Induced Arthritis: Further Characterization in a Rodent Model of Collagen Induced Arthritis
Kalyan Chakravarthy¹, Robert Faltus¹, Anwar Murtaza¹ and Milenko Cicmil², ¹Pharmacology, Merck Research Laboratories, Boston, MA, ²Merck Research Laboratories, Boston, MA
Background/Purpose: We developed a novel mono-arthritic multi-flare Rat Streptococcal Cell Wall (SCW) model which captures certain aspects of disease with flares and remission of inflammation…
Abstract Number: 1840 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes Following Exposure to Abatacept during Pregnancy
M Kumar¹, L Ray¹, S Vemuri² and T Simon¹, ¹Bristol-Myers Squibb, Hopewell, NJ, ²Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Limited data are currently available in the medical literature to guide counseling of patients regarding pregnancy outcomes when treated with abatacept, a selective T-cell…
Abstract Number: 132 • 2014 ACR/ARHP Annual Meeting
Do Ultrasound (PDUS) and DAS28 Measure Different Aspects of Disease Activity? Analyses from the First Prospective International Phase IIIb Study of PDUS Response in Abatacept-Treated Patients with Rheumatoid Arthritis (RA)
Maria-Antonietta d'Agostino¹, M Boers², R Wakefield³, H Berner Hammer⁴, O Vittecoq⁵, M Galeazzi⁶, P Balint⁷, I Möller⁸, A Iagnocco⁹, E Naredo^10,11, M Ostergaard¹², C Gaillez¹³, E Barre¹⁴, M Le Bars¹⁵ and On behalf of the OMERACT-EULAR-Ultrasound Task Force, ¹AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ²VU University Medical Center, Amsterdam, Netherlands, ³University of Leeds, Leeds, United Kingdom, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵University Hospital, Rouen, France, ⁶University of Siena, Siena, Italy, ⁷Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Universitario Severo Ochoa, Madrid, Spain, ¹¹Hospital GU Gregorio Marañón, Madrid, Spain, ¹²Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ¹³Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ¹⁴Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁵Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: A composite (power Doppler/grayscale ultrasound [PDUS]) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, was shown to be responsive in RA patients with inadequate…
Abstract Number: 1578 • 2014 ACR/ARHP Annual Meeting
Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis – Preliminary Analysis from a Single Centre, Placebo-Controlled, Crossover Study
Agnes Szentpetery¹, Eric J. Heffernan², Muhammad Haroon³, Phil Gallagher¹, Anne-Marie Baker¹, Martina Cooney¹ and Oliver FitzGerald¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Radiology, St. Vincent's University Hospital, Dublin, Ireland, ³Newmarket On Fergus, Cork University Hospital, Cork, Ireland
Background/Purpose Abatacept is a soluble, fully human fusion protein which selectively inhibits T-cell activation via the CD80/CD86:CD28 co-stimulation pathway and decreases serum levels of inflammatory…
Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
Rossella Reggia¹, Franco Franceschini¹, Angela Tincani² and Ilaria Cavazzana¹, ¹AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…
Abstract Number: 1536 • 2014 ACR/ARHP Annual Meeting
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 1515 • 2014 ACR/ARHP Annual Meeting
The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate
T W J Huizinga¹, S E Connolly², Daniel E. Furst³, Vivian P. Bykerk⁴, Gerd Burmester⁵, B G Combe⁶, C S Karyekar², D Wong², L Trouw¹, R E M Toes⁷ and P Emery⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³University of California at Los Angeles, Los Angeles, CA, ⁴Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Charité – University Medicine Berlin, Berlin, Germany, ⁶Montpellier University Hospital, Montpellier, France, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a marker of RA and may contribute to disease progression.1,2 ACPA analysis in patients offers the opportunity to estimate…
Abstract Number: 1520 • 2014 ACR/ARHP Annual Meeting
Gene Expression Analyses of Abatacept- and Adalimumab-Treated Patients from the Ample Trial
S Bandyopadhyay¹, M Maldonado¹, M Schiff², ME Weinblatt³, Roy Fleischmann⁴ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The distinct mechanisms of action (MoA) of abatacept (ABA) and adalimumab (ADA) are expected to manifest in different transcriptional profiles in RA patients (pts).…
Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Anders Gülfe¹, Johan A. Karlsson² and Lars-Erik Kristensen³, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ³Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].